-
1
-
-
13944266313
-
Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration
-
DOI 10.1167/iovs.04-0601
-
Gaudreault J, Fei D, Rusit J et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46, 726-733 (2005). (Pubitemid 40270359)
-
(2005)
Investigative Ophthalmology and Visual Science
, vol.46
, Issue.2
, pp. 726-733
-
-
Gaudreault, J.1
Fei, D.2
Rusit, J.3
Suboc, P.4
Shiu, V.5
-
2
-
-
33645331188
-
Tolerability and efficacy of multiple escalating doses of ranibizumab Lucentis) for neovascular age-related macular degeneration
-
Rosenfeld PJ, Heier JS, Hantsberger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 13(4), 623-632 (2006).
-
(2006)
Ophthalmology
, vol.13
, Issue.4
, pp. 623-632
-
-
Rosenfeld, P.J.1
Heier, J.S.2
Hantsberger, G.3
Shams, N.4
-
3
-
-
33645641520
-
Ranibizumab for treatment of neovascular age-related macular degeneration: A Phase I/II multicenter, controlled, multidose study
-
Heier JS, Antoszyk AN, Pavan PR et al. Ranibizumab for treatment of neovascular age-related macular degeneration: A Phase I/II multicenter, controlled, multidose study. Ophthalmology 113(4), 633-642 (2006).
-
(2006)
Ophthalmology
, vol.113
, Issue.4
, pp. 633-642
-
-
Heier, J.S.1
Antoszyk, A.N.2
Pavan, P.R.3
-
4
-
-
33749445317
-
Ranibizumab for neovascular age-related macular degeneration
-
DOI 10.1056/NEJMoa054481
-
Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006). (Pubitemid 44511557)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.14
, pp. 1419-1431
-
-
Rosenfeld, P.J.1
Brown, D.M.2
Heier, J.S.3
Boyer, D.S.4
Kaiser, P.K.5
Chung, C.Y.6
Kim, R.Y.7
-
5
-
-
33749451356
-
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
-
DOI 10.1056/NEJMoa062655
-
Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus Verteporfin photodynamic therapy for neovascular macular degeneration. N. Engl. J. Med. 355, 1432-1444 (2006). (Pubitemid 44511558)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.14
, pp. 1432-1444
-
-
Brown, D.M.1
Kaiser, P.K.2
Michels, M.3
Soubrane, G.4
Heier, J.S.5
Kim, R.Y.6
Sy, J.P.7
Schneider, S.8
-
6
-
-
38349172455
-
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
-
Regillo CD, Brown DM, Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am. J. Ophthalmol. 145, 239-248 (2008).
-
(2008)
Am. J. Ophthalmol.
, vol.145
, pp. 239-248
-
-
Regillo, C.D.1
Brown, D.M.2
Abraham, P.3
-
7
-
-
36448963442
-
The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization
-
DOI 10.1007/s00417-007-0638-x
-
Massacesi AL, Sacchi L, Bergamini F, Bottoni F. The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization. Graefe's Arch. Clin. Exp. Ophthalmol. 246, 89-92 (2008). (Pubitemid 350162687)
-
(2008)
Graefe's Archive for Clinical and Experimental Ophthalmology
, vol.246
, Issue.1
, pp. 89-92
-
-
Massacesi, A.L.1
Sacchi, L.2
Bergamini, F.3
Bottoni, F.4
-
8
-
-
74549137478
-
Ranibizumab (lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials
-
Mitchell P, Korobelnik JF, Lanzetta P et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials. Br. J. Ophthalmol. 94, 2-13 (2010).
-
(2010)
Br. J. Ophthalmol.
, vol.94
, pp. 2-13
-
-
Mitchell, P.1
Korobelnik, J.F.2
Lanzetta, P.3
-
9
-
-
57949094834
-
Ranibizumab versus Verteporfin photodynamic therapy for neovascular macular degeneration: Two-year results of the anchor study
-
Brown DM, Michels M, Kaiser PK et al. Ranibizumab versus Verteporfin photodynamic therapy for neovascular macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 116, 57-65 (2009).
-
(2009)
Ophthalmology
, vol.116
, pp. 57-65
-
-
Brown, D.M.1
Michels, M.2
Kaiser, P.K.3
-
10
-
-
79955631484
-
Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study
-
Schmidt-Erfurth U, Eldem B, Guymer R et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study. Ophthalmology 118, 831-839 (2011).
-
(2011)
Ophthalmology
, vol.118
, pp. 831-839
-
-
Schmidt-Erfurth, U.1
Eldem, B.2
Guymer, R.3
-
11
-
-
77956056292
-
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 2
-
Abraham P, Yue H, Wilson L et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 2. Am. J. Ophthalmol. 150, 315-324 (2010).
-
(2010)
Am. J. Ophthalmol.
, vol.150
, pp. 315-324
-
-
Abraham, P.1
Yue, H.2
Wilson, L.3
-
12
-
-
33947403618
-
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration
-
Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol. 143, 566-583 (2007).
-
(2007)
Am. J. Ophthalmol.
, vol.143
, pp. 566-583
-
-
Fung, A.E.1
Lalwani, G.A.2
Rosenfeld, P.J.3
-
13
-
-
67149101784
-
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study
-
Lalwani GA, Rosenfeld PJ, Fung AE et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am. J. Ophthalmol. 148, 43-58 (2009).
-
(2009)
Am. J. Ophthalmol.
, vol.148
, pp. 43-58
-
-
Lalwani, G.A.1
Rosenfeld, P.J.2
Fung, A.E.3
-
14
-
-
79953295148
-
Safety and efficacy of flexible dosing regimen of ranibizumab in neovascular age-related degeneration: The SUSTAIN study
-
Holz FG, Amoaku W, Donate JD et al. Safety and efficacy of flexible dosing regimen of ranibizumab in neovascular age-related degeneration: The SUSTAIN study. Ophthalmology 118, 663-671 (2011).
-
(2011)
Ophthalmology
, vol.118
, pp. 663-671
-
-
Holz, F.G.1
Amoaku, W.2
Donate, J.D.3
-
15
-
-
36249002808
-
Ranibizumab for predominantly classic neovascular age-related macular degeneration: Sub-group analysis of first year ANCHOR results
-
Kaiser PK, Brown DM, Zhang K et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: Sub-group analysis of first year ANCHOR results. Am. J. Ophthalmol. 144, 850-857 (2007).
-
(2007)
Am. J. Ophthalmol.
, vol.144
, pp. 850-857
-
-
Kaiser, P.K.1
Brown, D.M.2
Zhang, K.3
-
16
-
-
33846586501
-
Sub-group analysis of the MARINA study of ranibizumab in neovascular age-related macula degeneration
-
DOI 10.1016/j.ophtha.2006.10.045, PII S0161642006014849
-
Boyer DS, Antoszyk AN, Awh CC et al. Sub-group analysis of the MARINA study of ranibizumab in neovascular age-related macula degeneration. Ophthalmology 114, 246-252 (2007). (Pubitemid 46172497)
-
(2007)
Ophthalmology
, vol.114
, Issue.2
, pp. 246-252
-
-
Boyer, D.S.1
Antoszyk, A.N.2
Awh, C.C.3
Bhisitkul, R.B.4
Shapiro, H.5
Acharya, N.R.6
-
17
-
-
34748844162
-
Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration
-
Kaiser PK, Blodi BA, Shapiro H et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114, 1868-1875 (2007).
-
(2007)
Ophthalmology
, vol.114
, pp. 1868-1875
-
-
Kaiser, P.K.1
Blodi, B.A.2
Shapiro, H.3
-
18
-
-
84984756571
-
The royal college of ophthalmologists interim recommendations for the management of patients with age-related macular degeneration
-
Amoaku WM. The royal college of ophthalmologists interim recommendations for the management of patients with age-related macular degeneration. Eye 22, 864-868 (2008).
-
(2008)
Eye
, vol.22
, pp. 864-868
-
-
Amoaku, W.M.1
-
19
-
-
70450201592
-
Ranbizumab: The clinician's guide to commencing, continuing, and discontinuing treatment
-
Amoaka WM. Ranbizumab: The clinician's guide to commencing, continuing, and discontinuing treatment. Eye 23, 2140-2142 (2009).
-
(2009)
Eye
, vol.23
, pp. 2140-2142
-
-
Amoaka, W.M.1
-
20
-
-
69249222585
-
A Phase III study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration
-
Boyer DS, Heier JS, Brown DM et al. A Phase III study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116(9), 1731-1739 (2009).
-
(2009)
Ophthalmology
, vol.116
, Issue.9
, pp. 1731-1739
-
-
Boyer, D.S.1
Heier, J.S.2
Brown, D.M.3
|